Skandinaviska Enskilda Banken Ab (Publ) Collegium Pharmaceutical, Inc Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 10, 2021	SELL	$21.74 - $25.28 $723,942 - $841,824	-33,300 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$17.83 - $22.29 $738,161 - $922,806	-41,400 Reduced 55.42%	33,300 $667,000
Q3 2020 Nov 12, 2020	SELL	$15.78 - $20.82 $130,974 - $172,806	-8,300 Reduced 10.0%	74,700 $1.56 Million
Q2 2020 Aug 13, 2020	BUY	$15.49 - $23.51 $96,038 - $145,762	6,200 Added 8.07%	83,000 $1.45 Million
Q1 2020 Jun 05, 2020	BUY	$13.89 - $25.45 $1.07 Million - $1.95 Million	76,800 New	76,800 $1.25 Million
Q3 2019 Nov 08, 2019	SELL	$10.16 - $13.28 $151,384 - $197,872	-14,900 Closed	0 $0
Q2 2019 Aug 09, 2019	BUY	$10.62 - $16.59 $158,238 - $247,191	14,900 New	14,900 $196,000

254

36.9M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.12B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.